REMASTer: REcurrent Brain Metastases After SRS Trial

Protocol No
MONTERIS-CL10153-REMASTER
Staff Member
Max O Krucoff
Phase
N/A
Summary

The purpose of this study is to collect patient data to better understand the effectiveness, use,
and outcomes of the NeuroBlate® System with combined therapy. Since it became
commercially available in the USA in April 2013, the NeuroBlate® System has been used in over 3900 procedures at approximately 82 leading institutions across the United States.
The medical device that we are studying, NeuroBlate® System, has been approved by the U.S.
Food and Drug Administration for patients with metastatic brain cancer and radiation necrosis.
We want to compare how patients treated with this device do when compared to other routine
care for these conditions.

Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL